Physician profile
Patrick A Sleckman
NPI 1255759080
$1,298.14
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $394 · 2021: $352 · 2022: $124 · 2023: $55.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $55.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $55.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.46 | 2019-2020 | |
| Pfizer INC. | $111.14 | 2019-2021 | |
| Amgen INC. | $96.26 | 2020-2023 | Otezla, Repatha |
| Sage Therapeutics, LLC | $88.81 | 2020 | |
| Daiichi Sankyo INC. | $84.87 | 2019-2020 | |
| Amarin Pharma, INC. | $79.46 | 2020-2021 | |
| Glaxosmithkline, LLC. | $69.27 | 2020-2022 | |
| Lilly USA, LLC | $61.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.10 | 2019-2021 | |
| Organon LLC | $34.78 | 2023 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $31.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.92 | 2021 | |
| Currax Pharmaceuticals LLC | $30.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.19 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.73 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.15 | 2019 | |
| Abbvie INC. | $26.71 | 2019-2022 | |
| Vifor Pharma, INC. | $22.74 | 2020 | |
| Biogen, INC. | $17.67 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2019 | |
| Abbott Laboratories | $12.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.57 | 2020 | |
| Vivus LLC | $10.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Sleckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.